Cytokines are classically thought to stimulate downstream signaling pathways through monotonic activation of receptors. We describe a severe anemia resulting from a homozygous mutation (R150Q) in the cytokine erythropoietin (EPO). Surprisingly, the EPO R150Q mutant shows only a mild reduction in affinity for its receptor but has altered binding kinetics. The EPO mutant is less effective at stimulating erythroid cell proliferation and differentiation, even at maximally potent concentrations. While the EPO mutant can stimulate effectors such as STAT5 to a similar extent as the wild-type ligand, there is reduced JAK2-mediated phosphorylation of select downstream targets. This impairment in downstream signaling mechanistically arises from altered receptor dimerization dynamics due to extracellular binding changes. These results demonstrate how variation in a single cytokine can lead to biased downstream signaling and can thereby cause human disease. Moreover, we have defined a distinct treatable form of anemia through mutation identification and functional studies.
INTRODUCTION
The majority of receptor signaling pathways are generally thought to function through a simple model of activation, which then promotes downstream signal propagation by a variety of distinct mechanisms (Lemmon and Schlessinger, 2010; Spangler et al., 2015) . For G protein-coupled receptors (GPCRs), groundbreaking insight from human physiologic and pharmacologic responses has revealed the existence of functional selectivity (or, biased agonism), whereby a single receptor is capable of variable activation of distinct downstream pathways in response to different ligands (Kenakin, 2011; Wisler et al., 2014) . The extent to which other receptor signaling pathways utilize such functional selectivity in physiologic settings remains unclear, particularly for receptor signaling systems that require either homo-or hetero-dimerization for activation. Such signaling systems include receptor tyrosine kinases and cytokine receptors (Kovacs et al., 2015; Kovanen and Leonard, 2004; Lemmon et al., 2016; Lemmon and Schlessinger, 2010; Spangler et al., 2015) . Recent studies have shown that engineered bivalent antibody fragments can display biased agonism through altered geometry of cytokine receptor interactions (Moraga et al., 2015b) . Moreover, subtypes of cytokine classes, such as type I interferons, which signal through a common set of receptors, display selectivity toward specific physiologic responses as a result of alterations in receptor-ligand binding affinities (Spangler et al., 2015; Thomas et al., 2011; Wilmes et al., 2015) . How signals from other natural ligands are tuned in this way remains largely unexplored, however, as do the in vivo consequences of variable activation of specific signaling pathways downstream of cytokines.
In the context of GPCRs, functional selectivity (or, biased agonism) has been shown to arise from alteration of equilibrium binding affinity of a ligand to its receptor or from stabilization of particular receptor conformations as a result of ligand binding (Kenakin, 2011; Manglik et al., 2015; Wisler et al., 2014) . A variety of analytic methods have been developed to formalize this concept and primarily rely upon the measurement of the dissociation constant that an agonist has for a particular activity (potency) and the maximal achievable effect downstream of a particular signaling response (efficacy) (Kenakin, 2011; Rajagopal et al., 2011) . Indeed, metrics to quantify biased agonism, such as the transducer ratio, have relied upon comparisons between the efficacy and potency for a particular response (Kenakin et al., 2012) . In an analogous manner with GPCRs, recent studies of cytokine signaling have shown that both alteration of ligand-receptor affinities or stabilization of alternative conformational states can lead to biased agonism (Moraga et al., 2015b; Wilmes et al., 2015) . However, emerging evidence suggests that kinetic parameters may also have a key role in determining the extent of biased agonism observed in GPCR signaling (Klein Herenbrink et al., 2016) . Here, through the investigation of rare experiments of nature, we uncover a cytokinereceptor binding kinetic mechanism that alters receptor dimerization dynamics and causes biased downstream signaling by JAK2. Additionally, the insight gained through these functional studies has allowed us to successfully apply recombinant cytokine therapy in a patient with a rare mutation affecting cytokine signaling.
RESULTS

Identification of an EPO Mutation Causing Hypoplastic Anemia
While attempting to identify previously unknown genetic etiologies causing Diamond-Blackfan anemia (DBA) (Danilova and Gazda, 2015; Landowski et al., 2013; Sankaran et al., 2012 )-a disorder where red blood cell production is impaired due to a selective absence of erythroid precursors and progenitors in the bone marrow-we encountered the case of a 6 year old male child of a first-cousin consanguineous union who was diagnosed at 1 year of age with DBA and required regular transfusions. The child was started on and responded to corticosteroids at 1.5 years of age, but severe steroid-induced osteopenia necessitated transitioning back to a chronic trans- fusion regimen 1 year later. When the child was 6 years of age, a decision was made to proceed with a bone marrow transplant from a fully human leukocyte antigen (HLA)-matched maternal aunt. Despite the achievement of full donor chimerism, the patient continued to require packed red blood cell transfusions. Gastrointestinal graft versus host disease occurred soon after chimerism was achieved, and by day 150 following the transplant, the patient developed capillary leak syndrome and passed away of resultant complications.
Despite the typical clinical and pathologic appearance of DBA ( Figure 1C , Figure S1 ), a number of features made this case unusual. First, stem cell transplantation in DBA normally cures the anemia once donor chimerism is achieved (Roy et al., 2005) . Second, given that DBA is generally thought to display autosomal dominant inheritance, it was surprising to discover that the parents of the child were unaffected first cousins ( Figure 1A ) (Sankaran et al., 2012) . Given these atypical features, whole-exome sequencing of the child was undertaken in an attempt to identify an underlying genetic etiology (Figure 1A) (Casanova et al., 2014; Sankaran et al., 2012; Sankaran et al., 2015) . After filtering out common genetic variation, no potential causal mutations could be identified in genes known to cause DBA (Landowski et al., 2013; Sankaran et al., 2012) . Given that the parents were first cousins and unaffected, we hypothesized that a homozygous recessive mutation might underlie the anemia. By examining candidate homozygous recessive mutations, a previously unknown homozygous mutation in EPO was identified (chr7:100,320,704 G>A). This mutation was absent from a cohort of 60,706 individuals depleted for Mendelian disease (Lek et al., 2016) and occurred in the heterozygous state in the unaffected sibling and parents, fitting the model of complete penetrance for an autosomal recessive mutation (Figures 1A and 2B, Tables S1, S2, and S3) . The identified missense variant would result in substitution of glutamine for arginine at position 150 of the mature erythropoietin (EPO) protein (herein R150Q). Curiously, when EPO levels were measured while the patient was on regular transfusions (which will suppress the production of EPO), they were noted to be over 100-fold elevated (767 mU/mL; normal range of 3.5-17.6 mU/mL), suggesting that appropriate and elevated levels of the mutant EPO could be achieved.
The EPO R150Q Variant Primarily Alters LigandReceptor Binding Kinetics
Prior literature has shown the importance of the R150 residue in mediating interactions at the high affinity binding site (site 1) on the EPO receptor (EPOR) (Figures 2A and 2B ) (Bunn, 2013; Elliott et al., 1997; Syed et al., 1998; Wen et al., 1994) . Although mutations of the R150 site have been noted to mildly impair binding, the precise phenotypic effects of such mutations have not been examined in greater detail (Bunn, 2013) . To directly assess the effect of this mutation, we produced recombinant wild-type (WT) and mutated EPO. The EPO variant was well expressed and behaved similarly to the WT version ( Figure S2A ). Electrospray mass spectrometry confirmed the purity and normal glycosylation pattern of the mutant ( Figure S2B ). EPO R150Q was (A) The structure of the EPO receptor (EPOR) asymmetric dimer is shown with the regions on site 1 and site 2 highlighted in the structure. The R150 and S100 residues that were mutated are shown at these sites. (B) A zoomed in view of the structure shows salt bridges formed between the R150 residue on EPO and the side chains on site 1 of EPOR (show in blue). (C) Concentration dependent binding of EPO wildtype (WT) and R150Q mutant to immobilized EPOR are shown in black and red, respectively. The binding was measured using surface plasmon resonance. Means ± SEM for four independent experiments are shown. (D) Concentration dependent binding of EPO wildtype (WT) and R150Q mutant in the background of the site 2 S100E mutation to immobilized EPOR are shown in black and red, respectively. The binding was measured using surface plasmon resonance. Means ± SEM for two independent experiments are shown. (E) Surface plasmon resonance traces at concentrations of 50 nM for WT and 62.5 nM for R150Q EPO in the S100E mutated background are shown in black and red, respectively, with an overlying 1:1 kinetic fit shown with white dotted lines. Association and dissociation phases are indicated. See also Figure S2 .
capable of forming a complex with EPOR of comparable stability to the WT when assessed by multi-angle light scattering coupled to size exclusion chromatography (SEC-MALS) ( Figures S2C and S2D ). This finding suggested that there was likely a comparable affinity between EPOR and both the WT and R150Q forms of EPO. However, we could not obtain a precise measurement of affinity with SEC-MALS and therefore turned to surface plasmon resonance (Jenni et al., 2015; Moraga et al., 2015b) , which revealed the mutated EPO had a dissociation constant (K D ) that was reduced by only $3-fold (Table S4, Figure 2C ). It was therefore surprising that the elevated serum EPO levels in the patient could not compensate for this mildly reduced affinity. Since binding kinetics could not readily be determined given the multi-site interaction of EPO and EPOR, we mutated the low affinity binding site of EPO (site 2, S100E mutation) ( Figure 2A ) (Bunn, 2013; Elliott et al., 1997; Syed et al., 1998) . By comparing the WT and R150Q-mutated EPO in the S100E background (allowing only site 1 interactions), we could show that the K D of site 1 binding was reduced 8-fold in the R150Q mutant ( Figure 2D , Table S4 ). Interestingly, the R150Q mutation resulted in a 12-fold faster on-rate (k on ), as well as a 233-fold faster off-rate (k off ) ( Figure 2E , Figure S2E , Table S4 ). These findings demonstrate that the R150Q mutation only mildly affects the overall affinity, but significantly alters the kinetics of the cytokine's interaction with EPOR, which could have important consequences for downstream signaling by analogy with other receptor systems (Klein Herenbrink et al., 2016; McKeithan, 1995) .
Increased Concentrations of EPO Mutant Cannot Overcome Impaired Erythropoiesis
Since the R150Q mutation appeared to alter erythropoiesis in vivo, we examined its effects on erythroid cells in vitro to gain further insight into how it causes disease. We assessed the overall proliferative response of the human erythroid cell line, UT7 (Moraga et al., 2015b) , to the EPO variant and found that the potency for maximal proliferation was reduced by $100-fold for R150Q EPO (from 10 À9 M to 10 À7 M), while overall efficacy was also reduced by 20% (p = 0.00068, Figure 3A ). This observation suggested that even at concentrations of ligand demonstrating maximal potency (i.e., 10 À7 M), the mutated EPO cannot achieve the same effect on cell proliferation as is obtained with WT EPO-implying that when the R150Q EPO concentration is increased to account for affinity loss (as in the patient), it still cannot properly stimulate erythropoiesis. Using the S100E EPO variants, we further demonstrated that the interaction of site 2 was absolutely required to mediate the proliferative response in these cells ( Figure S3A ). We then turned to primary human CD34 + hematopoietic stem and progenitor cells (HSPCs), which can be cultured with specific cytokines over multiple phases to induce differentiation into mature red blood cells, closely mimicking multiple features of endogenous in vivo erythropoiesis Ludwig et al., 2014; Ulirsch et al., 2016) . At equimolar concentrations of EPO (10 À9 M), the R150Q mutant failed to support normal erythroid expansion or differentiation, as documented by a significant reduction in growth, impaired maturation, and outgrowth of non-erythroid cells ( Figures 3B-3E , Figures S3B-S3D ). Even at concentrations where its maximal measured potency was achieved (10 À7 M), R150Q-mutated EPO was impaired in its ability to promote erythroid expansion or maturation of the HSPCs ( Figures 3B-3E , Figures S3C and S3D ). Thus, simply adding R150Q-mutated EPO at higher concentrations to overcome its slight affinity defect does not allow it to behave like the WT ligand. In tandem with the results from the UT7 erythroid cells, these observations suggest that biased or partial activation of downstream pathways might underlie the pathology of the R150Q EPO mutation.
Biased Agonism of Select Downstream Effectors by EPO R150Q
A major downstream effector of EPO signaling is the transcription factor STAT5, which is phosphorylated by the EPOR-associated tyrosine kinase, JAK2, and localizes to the nucleus in erythroid cells after stimulation with EPO (Bunn, 2013; Giani et al., 2016; Kuhrt and Wojchowski, 2015) . We measured the dosage-dependent response of STAT5 phosphorylation to either WT or R150Q-mutated EPO in erythroid cells. Consistent with the effects observed for proliferation in these cells, over the course of 30 min there was a comparable dose response with maximal potency of phosphorylation achieved at 10 À9 M for WT and 10 À7 M for R150Q-mutated EPO ( Figure 4A ). The difference in maximal normalized levels of STAT5 phosphorylation was less than 2%, and there was no difference between the absolute levels of STAT5 phosphorylation (p = 0.938, Figure S4A ). Figure S3 .
The time-dependent stimulation of STAT5 phosphorylation largely overlapped, with peak stimulation observed at 15 min ( Figure 4B , Figure S4B ). Given that STAT5 phosphorylation was observed to be similar at maximally potent concentrations, this suggested that other downstream targets might show biased activation in this setting, arising from the different binding kinetics of R150Q EPO. A recent analysis of engineered synthetic ligands for EPOR has demonstrated that biased signaling can be detected by broadly surveying a panel of phosphorylated substrates (Moraga et al., 2015b) . We therefore undertook an intracellular flow cytometric analysis of such phosphorylated substrates in erythroid cells stimulated with either WT or R150Q-mutated EPO at maximally potent concentrations (10
À9
M for WT and 10 À7 M for R150Q) . Although many major targets-like STAT5-showed similar profiles for both EPO ligands ( Figure 4C ), a subset of targets showed altered activation (Tables S5 and S6 ). Indeed, the overall profile of activation was shifted as a result of this subset of targets having reduced phosphorylation due to the R150Q mutant ( Figure 4D ). The phosphorylation of STAT1 and STAT3, which are both activated downstream of EPO (Moraga et al., 2015b) , were the most significantly impaired targets (at both 15 and 30 min time points) at maximally potent concentrations (10 À7 M) of the R150Q EPO ( Figure 4E ). See also Figure S5 .
erythroid cells ( Figure S5C ). To define whether STAT1 and STAT3 were necessary for EPO-induced erythroid cell proliferation, we targeted these two factors separately or in tandem with short hairpin RNAs and noted a reduction in cell proliferation in UT7 cells in all cases ( Figure S5D ). Importantly, the targeted STAT was consistently suppressed ( Figures S5E-S5G ). Interestingly, even with short-term suppression (over the course of days), other STATs were noted to change in expression, consistent with compensatory responses. In cultures of HSPCs differentiating toward the erythroid lineage, there was decreased growth and mildly impaired differentiation (as evident from an accumulation of CD235a À /CD71 À non-erythroid cells) with suppression of STAT1, STAT3, or both proteins (Figures S5H and S5I) . These results are supported by prior studies in human erythroid cells and mice in vivo, demonstrating the importance of these distinct pathways in EPO signaling (Halupa et al., 2005; Kirito et al., 2002; Kirito et al., 1997) . We would note that although decreased STAT1 and STAT3 activation might underlie some of the observed phenotypes with the R150Q EPO, they are unlikely to be the sole effectors resulting in the observed impairment in erythropoiesis. Impaired activation of other pathways, such as RAS-MAP kinase signaling, might additionally contribute to the observed phenotypes ( Figure 4C ) (Kuhrt and Wojchowski, 2015) . The dramatic reduction in the phosphorylation of STAT1 and STAT3, but not of STAT5, downstream of this mutated ligand suggested that either an upstream activator or a downstream regulator of STAT phosphorylation was affected by the mutant ligand. We reasoned that understanding the basis for this biased agonism of specific downstream effectors could provide mechanistic insight into the underlying altered activity of the mutated EPO. STAT transcription factors are dephosphorylated by the phosphatases SHP-1 (PTPN6) and SHP-2 (PTPN11) (Chen et al., 2003; Wu et al., 2002; Yu et al., 2000) . We utilized a selective inhibitor of SHP-1 and SHP-2, NSC-87877 (Chen et al., 2006) , and observed no major change in EPO-induced STAT1, STAT3, or STAT5 phosphorylation in the erythroid cells at various doses ( Figure 5C ), suggesting that the activity of these phosphatases was unlikely to underlie the observed bias in the pattern of STAT phosphorylation.
Variation at the level of upstream activity therefore appeared more likely to be responsible for the selective activation of downstream effectors. Ligand-induced dimerization of the EPOR results in activation of the associated tyrosine kinase JAK2, which in turn is able to directly phosphorylate the STAT transcription factors (Bunn, 2013; Kuhrt and Wojchowski, 2015; Moraga et al., 2015b; Spangler et al., 2015) . We suppressed JAK2 activity with the specific kinase inhibitor ruxolitinib and examined the activation of the three STAT transcription factors (Quintá sCardama et al., 2010; Tefferi, 2012) . Surprisingly, we observed biased antagonism when we suppressed EPO-stimulated JAK2 activation ( Figure 5D ). There was a greater than 20-fold difference in the potency of ruxolitinib inhibition of STAT1 and STAT3 phosphorylation (IC 50 of 1.3 3 10 À8 M), as compared with STAT5 phosphorylation (IC 50 of 2.8 3 10 À7 M) ( Figure 5D ).
Such biased antagonism by ruxolitinib has only rarely been reported (Tefferi, 2012) .
We saw reduced proliferation of the erythroid cells at ruxolitinib concentrations that would impair STAT1 and STAT3, but not STAT5, phosphorylation (e.g., 4 3 10 À8 M) ( Figure 5E ), similar to what was observed for the R150Q EPO mutant ( Figure 3A ). This demonstrates that an impairment in erythroid cell proliferation and STAT1 and STAT3 phosphorylation is observed with both the kinetically-biased EPO mutant or with low-level JAK2 inhibition. We could obtain similar results as observed for ruxolitinib using another specific and mechanistically distinct JAK2 inhibitor, CHZ868 (Figures S5J and S5K) (Meyer et al., 2015) . These observations suggested that the functional selectivity of the EPO R150Q mutant could be due to impaired JAK2 activation. To directly test this, we added low dose (4 3 10 À8 M) ruxolitinib to varying concentrations of either the R150Q-mutated or WT EPO. The selective inhibition of JAK2 resulted in a similar maximal efficacy of erythroid cell proliferation for the R150Q and WT forms of EPO ( Figure 5F , Figure S5L ). Importantly, treatment with this low dose of ruxolitinib dramatically reduced phosphorylation of STAT1 and STAT3 to similar levels with maximally potent concentrations of either the WT or R150Q EPO ligands, while minimally affecting STAT5 phosphorylation levels (Figure 5G ). These results demonstrate that the impaired erythropoiesis and functional selectivity of the R150Q EPO are due to impaired JAK2 activation. If JAK2-independent pathways were playing additional roles in the impaired activation downstream of the R150Q EPO mutant, a sizable residual difference should be seen in the maximal erythroid cell proliferation after ruxolitinib treatment. However, this was not the case (difference of <7%, p = 0.065; Figure S5L ), and thus JAK2 activation appeared to be a primary mediator of the impaired erythropoiesis due to the R150Q-mutated EPO.
Altered EPOR Dimerization Dynamics Limit JAK2 Activation by EPO R150Q
We have shown that the EPO R150Q mutation, which was identified in a patient with congenital hypoplastic anemia, alters the kinetics of ligand-receptor binding but has only a moderate effect on the overall binding affinity. Despite having elevated EPO levels, the patient was unable to compensate for the impaired erythropoiesis present, demonstrating that this mutant alters the properties of EPO signaling. We have further shown that this kinetically-biased mutant form of EPO results in skewed activation of downstream signaling due to impaired JAK2 activity. However, the exact mechanism by which the alterations of ligand-receptor binding result in impaired JAK2 activation remain unclear. Recent studies have demonstrated the value of using total internal reflection fluorescence (TIRF) microscopy of labeled receptor molecules on the cell surface to visualize cytokine receptor dimerization dynamics and activation (Moraga et al., 2015a; Moraga et al., 2015b; Wilmes et al., 2015) . We reasoned that probing the assembly of EPOR at the single molecule level could provide insight into mechanisms underlying the altered activity of the R150Q EPO mutant. We utilized cells stably expressing EPOR, N-terminally tagged with a meGFP, which was rendered non-fluorescent (by the Y67F mutation). This tag (mXFP) is recognized by dye-conjugated anti-GFP nanobodies, allowing quantitative fluorescence labeling of EPOR at the cell surface of live cells. Well-balanced dual-color labeling was achieved using equal concentrations of nanobodies either conjugated with RHO11 or with DY647 (Moraga et al., 2015b; Wilmes et al., 2015) . JAK2 was co-expressed in order to ensure full functionality and expression of the receptor system (Huang et al., 2001) .
We used dual-color TIRF imaging to visualize the spatiotemporal dynamics of EPOR after exposure to different concentrations of either the WT or mutant EPO ligands ( Figure 6A , Figure S6 , Movie S1). Single-molecule co-localization and co-tracking analysis was used to identify correlated motion (co-locomotion) of the spectrally separable fluorescent molecules, which was taken as readout for productive dimerization of EPOR. In the absence of stimulation, there was very little dimerization observed, which could be increased significantly upon stimulation with maximally potent concentrations of WT EPO ( Figures 6B and 6C ). This observation strongly supports the concept that the EPO ligand induces dimerization of EPOR and thus results in downstream activation through this mechanism (Moraga et al., 2015b) (Figure 6B ). When we examined the R150Q mutant, we noted consistently reduced levels of dimerization, even at maximally potent concentrations (100 nM ligand) ( Figure 6C ). The extent of dimerization was on average 1.2-fold reduced (p = 0.012) as compared to the WT at maximally potent concentrations (1 nM). Importantly, excess levels of the WT EPO (100 nM) impaired dimer formation, given that high affinity interactions with receptors are favored over the formation of an EPOR dimer complex at such high ligand concentrations. Consistent with this observation, the S100E EPO, which only has an intact site 1 for EPOR, but cannot bind to the lower affinity site (site 2), failed to elicit dimerization even at high concentrations of ligand ( Figure 6C ). Collectively, these results show that the R150Q mutant has a reduced ability to promote EPOR dimer formation, resulting in reduced JAK2 activation even at maximally potent concentrations. Formation of such EPOR dimers is critical for the full activation of JAK2 (Silvennoinen and Hubbard, 2015) . Despite an increase in concentration to overcome any affinity deficit, the R150Q EPO failed to induce maximal receptor dimerization and proper signaling. Our observations demonstrate that ligand-receptor binding kinetics can affect receptor dimerization dynamics on an intact cell surface, and this in turn can modulate downstream signal transduction. be achieved through kinetic changes in cytokine-receptor interactions. Unfortunately, the proband identified with the EPO R150Q mutation passed away prior to mutation identification, as a result of complications stemming from the bone marrow transplantation procedure. While this work was undergoing revision, the parents of the proband had another child. Similar to the proband, this newborn infant was noted to be anemic, with a hemoglobin of $7 g/dL and an inappropriately low reticulocyte response, even after the period of the normal physiologic newborn nadir (Sankaran and Agrawal, 2013) . In addition, multiple measurements of serum EPO levels showed significantly elevated levels (>750 mU/mL at 108 and 150 days of life) without an appropriate erythropoietic response. Confirmatory sequencing revealed that this newborn infant also harbored the homozygous variant in EPO (chr7:100,320,704 G>A), resulting in the R150Q mutation ( Figures 7A and 7B) . As a result, after appropriate permissions were obtained, a trial of recombinant EPO therapy was initiated (given at 50 units/kg/dose, three times a week). Since WT EPO should be able to readily compete with the R150Q mutant, as occurs in the heterozygous parents and sibling, we expected that recombinant EPO therapy should work in this patient. While treatment has only been performed over the course of eleven weeks, the child has shown a robust and appropriate reticulocyte response, with a steady rise in hemoglobin levels into the normal range ( Figure 7C ). Without such therapy, it is very likely that the anemia would have progressively worsened and would have likely necessitated initiation of transfusion therapy, as occurred in the elder sibling of this infant and as is often seen in other cases of congenital anemia. Importantly, recombinant EPO therapy has been trialed in DBA patients previously with no response noted (Narla et al., 2011) . Therefore, this anemia due to the EPO R150Q mutation defines a distinct treatable blood disorder.
DISCUSSION
By using both genetic and experimental studies (Casanova et al., 2014; MacArthur et al., 2014) , we identified a missense variant in the EPO gene that results in congenital hypoplastic anemia. These rare experiments of nature illustrate how functional selectivity in receptor signaling can have important physiologic consequences and, to the best of our knowledge, provide the first examples of how this can result in human disease. Despite the ability of the proband and his sibling with the homozygous R150Q mutations to upregulate EPO production to levels that should offset induced affinity changes, these patients could not compensate for the defect in EPO signaling to enable normal erythropoiesis. Our studies show that the R150Q EPO cannot achieve the same maximal efficacy as WT EPO in terms of promoting erythroid differentiation or proliferation. Treatment with corticosteroids, which can expand early erythroid progenitors independently from EPO (Flygare et al., 2011) , allowed the proband to have an improvement in the anemia, which shows that some signaling through EPOR is still possible with the R150Q mutant, as we directly demonstrate through in vitro studies. In addition, the infant sister of the proband who had a reticulocytopenic anemia demonstrated a robust hematologic response to treatment with recombinant EPO, suggesting that through the functional studies we have performed, we have been able to define a treatable form of congenital hypoplastic anemia. This provides a rare example of how whole-exome sequencing and follow-up studies can lead to successful and modified treatment approaches, as has been recently described for specific metabolic disorder cases ( Tarailo Our results are consistent with a model of altered ligand-receptor binding kinetics, resulting in impaired receptor dimerization dynamics. More rapid dissociation of the R150Q EPO ligand (t 1/2 of less than 10 s for the R150Q mutant, as compared to greater than 5 min for WT) prevents optimal EPOR signaling by restricting activation of JAK2 and thereby limiting its ability to fully activate specific downstream effectors, including STAT1 and STAT3. We observe that these particular targets are more sensitive to inhibition by the JAK2 inhibitors, ruxolitinib and CHZ868. These findings demonstrate that specific JAK2 targets can have variable propensities for phosphorylation, depending upon the extent of JAK2 activation. We show that the R150Q EPO ligand behaves as a partial agonist for JAK2 activation at maximal potency and therefore results in biased signaling. Overall, our findings from a pathologic case demonstrate a mechanism through which tuning of intracellular signaling downstream of cytokine receptors can be achieved via alteration of JAK2 activation. It is likely that other cytokine signaling systems may take advantage of such tuning mechanisms to alter downstream signaling responses (Spangler et al., 2015) .
Several analyses have investigated kinetic proofreading in receptors (Klein Herenbrink et al., 2016; Lemmon et al., 2016; McKeithan, 1995; Thomas et al., 2011) , and their findings suggest that productive receptor signaling can only occur if the activating ligand remains bound for sufficient time to allow the multiple steps required for downstream receptor signaling to ensue-against the background of multiple rapid inactivation steps. Our results show how this mechanism can be of relevance to EPO and other cytokine signaling pathways. Faster dissociation of the mutant ligand prevents optimal EPOR dimerization and downstream JAK2 activation, demonstrating that kinetic parameters have a key role in determining the quality of signaling achieved downstream of such receptors. An important implication of these findings is that, analogous to biased agonists identified for various GPCRs (Kenakin, 2011; Wisler et al., 2014) , cytokine receptors can also display such behavior to altered ligands, and this can have important physiological consequences, as shown by the patient that led us to investigate this phenomenon. This also suggests that beyond alteration of conformation and affinity, which have previously been suggested as mechanisms for tuning cytokine signaling (Moraga et al., 2015b; Wilmes et al., 2015) , kinetic parameters can have a key role in altering downstream responses.
By applying the principle of functional selectivity, it may also be possible to design agonists that achieve specific physiologic responses downstream of endogenous cytokine pathways, while avoiding other untoward effects. Thus, modification of ligand-receptor kinetic parameters could tune downstream intracellular signaling responses and lead to more effective therapeutic manipulation of cytokine signaling. Our findings stress the importance of looking at downstream signaling by using multiparameter approaches, such as through surveys of a broad array of phosphorylated proteins (Knapp et al., 2017; Krutzik et al., 2011) . As in the case we have examined here, specific targets such as STAT5 show normal activation at maximally potent concentrations of the mutant ligand. However, the same extent of erythropoiesis can never be achieved with this mutant, as we show in vitro, which is completely consistent with what has been observed in vivo in the patients. Examining multiple responses allows for ascertainment of functional selectivity in such settings. Our findings that began with rare experiments of nature highlight the importance of considering both dynamic states of activation and the multidimensional nature of downstream responses in the context of cytokine signaling.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
UT7/EPO Cell Culture UT7/EPO cells were maintained in Dulbecco's Modified Eagle Medium (DMEM; GIBCO) with 10% of fetal bovine serum (FBS; Atlanta Biologicals), 1% of penicillin/ streptomycin (GIBCO), and 2 U/mL recombinant erythropoietin (EPO) (Amgen) (Moraga et al., 2015b) . The culture was passaged every 2-3 days. Cells were incubated at 37 C with 20% O 2 and 5% CO 2 . Research Center. CD34 + cells were cultured via a previously described culture system that allows complete maturation into enucleated red blood cells Ludwig et al., 2014) . The base media for erythroid differentiation was composed of 2% human AB plasma (obtained from the blood bank at Boston Children's Hospital), 3% human AB serum (Atlanta Biologicals), 1% of penicillin/ streptomycin, 3 U/mL heparin (Hospira), 10 mg/mL insulin (Lilly), 200 mg/mL transferrin (Sigma) in Iscove's Modified Dulbecco's Medium (IMDM; GIBCO). In Phase I (day 0-6), cultures were supplemented with 10 ng/mL stem cell factor (SCF), 1 ng/mL interleukin-3 (IL-3), and either with recombinant EPO from Amgen (3 U/mL), EPO WT (10 À9 M) or EPO R150Q (10 À9 or 10 À7 M) to initiate erythroid lineage commitment. In Phase II (day 7-13) and Phase III (day 14 onward), cultures were supplemented with SCF and EPO (either with WT or R150Q) or EPO alone, respectively, to promote further erythroid differentiation. Cells were incubated at 37 C with 20% O 2 and 5% CO 2 . Cell concentration was measured using an automatic cell counter (Beckman Coulter).
METHOD DETAILS Recombinant Protein Expression and Purification
Codon-optimized cDNAs for the extracellular region of human erythropoietin receptor (EPOR) and human erythropoietin (EPO) were synthesized (Genscript). The sequence was subcloned into a pFastbac plasmid for baculovirus driven expression in insect cells. The mature protein sequence followed the native signal peptide of each. A hexa-histidine tag was added to the amino terminus, following 193R of EPO, and following 249D of EPOR. Mutation of arginine 177 to glutamine -residue 150 of the mature EPO sequence after signal sequence processing and referred to as (EPO R150Q) -was introduced by site directed mutagenesis using the QuickChange Kit (Agilent Technologies). The EPO site II mutation of serine 127 to glutamic acid -residue 100 of the mature EPO sequence (S100E) -was introduced by site directed mutagenesis using the QuickChange Kit (Agilent Technologies).
EPO, EPO mutants, and the EPOR were expressed and purified as described (Jenni et al., 2015) . Trichoplusia ni cells were grown in Ex-Cell405 (Sigma-Aldrich) medium and infected at 1 million/ml. Supernatant was clarified 72 hr post infection by centrifugation and passed twice over cobalt resin (Clontech). For EPOR, protease inhibitors were added to the supernatant (aprotinin, leupeptin, and pepstatin). The resin was washed with 10 mM imidazole in Dulbecco's modified phosphate-buffered saline (Sigma-Aldrich) and eluted in the same buffer with 200 mM imidazole. After adding 10 mM ethylenediaminetetraacetic acid (EDTA) the protein was concentrated in a Centricon 10 kDa spin concentrator (Millipore) and then passed over a Superdex 200 10/300 GL size exclusion chromatography column (GE Healthcare Life Sciences) in 10 mM triethanolamine buffer (pH 8.0), with 150 mM NaCl.
Mass Spectrometry
Protein identity and purity were assessed by intact protein electrospray ionization fourier transform ion cyclotron resonance mass spectrometry (ESI-FTICR MS; Bruker Apex 3) after desalting samples by reversed-phase liquid chromatography (RPLC). Both WT and mutant R150Q EPO ran as single peaks on RPLC. The mass spectra of both proteins showed the same pattern of glycosylation, with the deconvoluted masses of all 9 major glycosylated species of the mutant shifted shifted 28 amu lower, consistent with the R150Q mutation.
Microcapillary LC/MS/MS of Coomassie stained bands digested with trypsin matched peptides corresponding to > 81% of human EPO. For the WT EPO sample the fragment 144-VYSNFLR-150 was isolated, whereas 144-VYSNFLQGK-152 was isolated for the R150Q mutant. The remaining unmatched peptide fragments include the predicted glycosylation sites.
Surface Plasmon Resonance
Using a Biacore T200 instrument (GE Life Sciences) EPOR was coupled to a series S CM5 chip (GE Life Sciences) after dilution to $500 nM in 10 mM acetate pH 5.2 buffer. A total of 700 response units (RUs) were stably coupled. 10 mM triethanolamine buffer (pH 8.0), with 100 mM NaCl was used as running buffer for equilibrium experiments. 150 mL of EPO or EPO R150Q was injected at various concentrations with a flow rate of 30 ml/min all at 8 C. A regeneration step of 25 mL of 10 mM acetate pH 5.0, 1 M NaCl between injections at a rate of 50 ml/min returned the baseline to % 5% of the initial RUs. Equilibrium (plateau) RUs were plotted against concentration and a non-linear regression analysis was carried out to determine dissociation constants (GraphPad Prism 6.0). The fit included a shared Bmax between wild-type and mutant, as each should give the same potential max response to the equivalent surface. Four separate experiments were combined to calculate the average and error. For kinetic experiments with the site II mutant (S100E) EPO ligands, the buffer included 0.05% Tween 20 (Polyethylene glycol sorbitan monolaurate). Maximum RUs were kept less than 100. 250 mL of EPO or EPO R150Q was injected in at various concentrations with a flow rate of 50 ml/min all at 15 C. A regeneration step of 25 mL of 10 mM acetate pH 5.0, 1 M NaCl between injections at a rate of 50 ml/min returned the baseline to % 5% of the initial RUs. Fitting was carried out with Biacore evaluation software.
Size Exclusion Chromatography-Multiangle Light Scattering (SEC-MALS)
This was performed essentially as described (Jenni et al., 2015) . SEC-MALS was carried out on a Dawn Heleos-II Multi-Angle static Light Scattering (MALS) detector (Wyatt) with the Optilab T-Rex refractive index detector (Agilent Technologies) after passing through a Superdex 200 5/150 GL column (GE Healthcare Life Sciences). A total of 15 mL of 40 mM EPO, EPO R150Q, or 38 mM EPO receptor extracellular region (EPOR) was injected. For the 1:1 ratios (Ligand: EPOR), 29 mM: 29 mM was injected. Fitting was done with Astra software using a dn/dc value of 0.179, which assumes 14% carbohydrate by mass for each protein.
Proliferation Assay UT7/EPO cells were cytokine starved overnight before plating. 5,000 or 10,000 cells were plated in 96-well plates (Corning) with the various recombinant EPO ligands (WT, R150Q, S100E, and R150Q+S100E) at a range of concentrations (0, 10 À14 -10 À6 M). For inhibitor experiments, UT7/EPO cells were cytokine starved as above and treated with vehicle (water or DMSO), NSC87877 (Tocris), ruxolitinib (Selleckchem), or CHZ868 (MedKoo) at a range of concentrations (0, 4x10 À10 -5x10 À6 M). The cytokine starved UT7/EPO cells were treated with vehicle (DMSO) or S3I-201 (Selleckchem) (75x10 À6 -500x10 À6 M). Cells were also treated with 40 nM of ruxolitinib with the recombinant EPO ligands (WT, R150Q) at a range of concentrations (0, 10 À12 -10 À6 M). Cells were incubated at 37 C with 20% O 2 and 5% CO 2 for 3 days before performing the MTT assay (ATCC) to assess proliferation. This was done following the manufacturer's protocol. Briefly, tetrazolium MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) was added to cells and incubated at 37 C for 3 hr. Subsequently, the detergent reagent was added and incubated at room temperature in the dark for 3 hr. The level of intracellular formazan resulting from cell proliferation was measured via absorbance at 570 nm using the EnSpire Multimode Plate Reader (PerkinElmer). To calculate the relative proliferation, the absorbance of blank wells (media only) and of wells containing unstimulated cells was subtracted from the absorbance for the other wells. The relative proliferation was calculated by normalizing all readings to the absorbance value of WT EPO at 10 À9 M.
Evaluation of Erythroid Maturation
To monitor the stages of erythroid maturation, Giemsa staining was performed. Differentiated cells were spun down using Shandon Cytospin (Thermo Electron Corporation) at 400 rpm for 3 min. Slides (Sigma) with cytocentifuged cells were stained with MayGrü nwald (Sigma) for 5 min at room temperature. After washing three times with deionized water for 30 s each, slides were stained with a 1:20 dilution of Giemsa (Sigma) for 15 min at room temperature. Slides were washed three times with deionized water followed by air drying, before mounting a coverslip (Thermo Scientific) with permount (Sigma). Each stage of erythroid maturation was manually counted after evaluating at least five different fields of a slide. Images were taken at 100x via on an Olympus BX51 microscope.
Flow Cytometry
Hematopoietic differentiation under treatment with EPO WT or EPO R150Q was evaluated and compared by flow cytometry. Cells were washed with a buffer containing 3% FBS in PBS, followed by staining with antibodies at 4 C in the dark for 20 min. Differentiated cells were stained with CD71-Fluorescein Isothiocyanate (FITC) and CD235a-Allophycocyanin (APC) for erythroid cell evaluation or CD11b/ CD41a-Phycoerythrin (PE) for non-erythroid myeloid cell evaluation. Propidium Iodide (PI; 1:1,000 dilution) was added for live/dead cell discrimination. All antibodies were stained at a 1:40 dilution, unless otherwise noted. A BD Accuri C6 Cytometer (BD Bioscience) was used to acquire flow cytometry data and all analysis was performed using FlowJo (version 10.0.8r1).
Phosphorylated STAT Assessment with Intracellular Flow Cytometry
Cytokine starved UT7/EPO cells were treated in a dose-dependent (0, 10 À12 -10 À6 M of EPO WT or R150Q for 30 min) or time-dependent (10 À9 or 10 À7 M of EPO WT or R150Q, respectively, for 15, 30, 60, and 180 min) manner. Starvation took place in base media without EPO present. UT7/EPO cells were generally starved overnight. When necessary, cytokine starved UT7/EPO cells were pretreated with inhibitors for 30 min in a dose-dependent (0, 5x10
À10
-5x10 À5 M of NSC87877, ruxolitinib, or CHZ868) followed by stimulation with EPO in the presence of inhibitors. For primary human erythroid cell cultures, CD34 + HSPCs were differentiated toward the erythroid lineage for 8 days followed by 4 hr of starvation in 1% bovine serum albumin (BSA) in IMDM. Subsequently, starved cells were stimulated with EPO (WT or R150Q) for 1 hr. Treated cells were gently mixed with pre-warmed Fixation Buffer (BD Bioscience) at 37 C for 10 min to fix cells. To permeabilize cells for intracellular staining, cells were resuspended in pre-chilled Perm Buffer III (BD Bioscience) for 30 min at 4 C. After three washes with 3% FBS in PBS, samples were stained either with Alexa Fluor-647 Mouse Antiphospho-STAT5 (pY694; 1:20 dilution), Alexa Fluor-647 Mouse Anti-phospho-STAT3 (pY705; 1:20 dilution), or Alexa Fluor-647 Mouse Anti-phospho-STAT1 (pY701; 1:20 dilution) for 1 hr in the dark at room temperature. A BD Accuri C6 Cytometer (BD Bioscience) was used to acquire mean fluorescent intensity (MFI) of phospho-STAT1/3/5-Alexa Fluor 647. The MFI of phospho-STAT1/3/5-Alexa Fluor 647 of gated single cells was calculated using FlowJo (version 10.0.8r1). Unstimulated UT7/EPO cells were used as a negative control. For pSTAT5 analysis in primary human erythroid cells, we gated on pSTAT5-positive cells for the analysis due to the heterogeneity of EPO response in such primary cell cultures. Data were acquired using either Accuri or LSR Fortessa instruments (Becton, Dickinson and Company).
Western Blotting
The cytokine starved UT7/EPO cells were stimulated with the recombinant EPO ligands (WT and R150Q) at a range of concentrations (0, 10 À12 -10 À6 M) for 30 min. Cells were collected and washed twice with cold PBS before lysing cells. Cells were lysed with RIPA buffer (Santa Cruz Technology) supplemented with PMSF, protease inhibitor cocktail, sodium orthovanadate, sodium pyrophosphate, beta-glycerol phosphate, and sodium fluoride. The protein lysates were added with loading dye and beta-mercaptoethanol and boiled at 95 C for 5 min. Equal amount of proteins (6.7 mg for STAT1, pSTAT1, STAT3, and pSTAT3; 1.7 mg for STAT5 and pSTAT5) were loaded for all conditions into 4%-20% Mini-PROTEAN TGX Precase Protein Gels for protein electrophoresis. Precision Plus Protein Kaleidoscope Prestained Standards (Bio-Rad) were used as a ladder to determine the molecular weight of proteins. Once the protein electrophoresis is completed, proteins were transferred to equilibrated PVDF membrane in 1x Tri/Glycine with 10% MeOH at 4C for 90 min. Then, the membrane was blocked with 3% BSA in TBS-T buffer for 1 hr at room temperature followed by incubation with the primary antibodies overnight at 4 C. Then, HRP conjugated secondary antibodies were incubated at 1 hr at room temperature. The membranes were developed by the incubation with substrates of the Clarity Western ECL Substrate (BioRad) for 5 min prior to developing into films. Films were scanned and bands were quantified using ImageJ 1.50i. The following primary antibody dilutions were used in the study: STAT1 (Santa Cruz Biotechnology; 1:200), pSTAT1 (BD Transduction Laboratories; 1:1,000), STAT3 (BD Transduction Laboratories; 1:5,000), pSTAT3 (BD Transduction Laboratories; 1:5,00), STAT5 (BD Transduction Laboratories; 1:500), pSTAT5 (Cell Signaling Technology; 1:2,000), and GAPDH (Santa Cruz Technology; 1:5,000). For secondary antibodies, goat anti-rabbit (Bio-Rad) was used in 1:20,000 and goat anti-mouse (Bio-Rad) was used in 1:10,000.
Phosphorylated Protein Analysis
Cytokine starved UT7/EPO cells were treated with EPO WT (10 À9 M) or EPO R150Q (10 À7 M) for 15 and 30 min after overnight starvation. Cells were fixed with 8% paraformaldehyde in PBS for 10 min at room temperature. Then, samples were resuspended in 5% bovine serum albumin in PBS and were stored at À80 C. The fixed cells were prepared for antibody staining according to standard protocols . Briefly, the fixed cells were permeabilized in 90% methanol for 15 min. The cells were stained with a panel of antibodies specific to the markers indicated (Primity Bio Pathway Phenotyping service, Table S5 ) and analyzed on an LSRII flow cytometer (Becton Dickinson). The mean fluorescence intensities (MFI) of the stimulated samples and unstimulated control samples were calculated. Ratios of the individual MFIs (using unstimulated as a reference) and of the distribution of MFIs at the different time points were analyzed using R 3.2 (R-project).
Viral Production and Infection
293T cells were cultured in DMEM with 10% FBS and 1% P/S. Cells were passaged with 0.25% Trypsin when they reached 80% confluency. A day before transfection, 293T cells were cultured with DMEM with 10% FBS in the absence of antibiotics. Cells were co-transfected with pVSVG, pD8.9, and a lentiviral genomic plasmid of interest (shLuc, shRNA targeting STAT1: TRCN0000004265, shRNA targeting STAT1: TRCN0000004267, shRNA targeting STAT3: TRCN0000020840, or shRNA targeting STAT3: TRCN0000020843). Media was replenished the day after transfection, and the supernatant containing virus was collected approximately 48 hr post-transfection. Collected supernatant was filtered through a 0.45 mm filter to proceed with viral infection. Approximately 300,000-500,000 UT7/EPO cells or CD34 + cells (day 2 in culture) were infected with the prepared lentivirus along with polybrene (8 mg/mL) and recombinant EPO (for UT7/EPO) or recombinant EPO/ SCF/ IL-3 (for CD34 + cells). Cells with viral supernatant were spun down at 2000 RPM for 90 min and were incubated at 37 C overnight. Virus was washed a day after infection, and puromycin selection (2 mg/mL for UT7/EPO cells and 1 mg/mL for HSPCs) was initiated on the following day for 30 hr. Puromycinselected UT7/EPO cells were plated for proliferation assays for 2 days, as described above. Cell concentrations after puromycin-selection of HSPC cell cultures were measured using an automated cell counter and growth was tracked on subsequent days of the erythroid differentiation culture (Beckman Coulter).
RNA Extraction, cDNA Synthesis, and Quantitative RT-PCR UT7/EPO cells with lentiviral infection were collected after puromycin selection. Cells were spun down at 600 g x 5 min at room temperature, and RNA was extracted with RNeasy Mini Kit following the manufacture's protocol (QIAGEN). Approximately 280 ng of RNA was used to synthesize cDNA with the iScript cDNA Synthesis Kit (Bio-Rad). Each reaction was incubated 5 min at 25 C for priming, 30 min at 46 C for reverse transcription, and additional 5 min at 95 C to inactivate the reverse transcriptase. Then, diluted cDNA (1:25) was mixed with iQ SYBR Green Supermix (Bio-Rad), 4 mM of primers listed above, and water to amplify using CFX 96 Read Time System (Bio-Rad) for 40 cycles. Samples without reverse transcriptase was used as negative controls for quantitative PCR reactions.
Single-Molecule Tracking, Co-localization, and Co-tracking Analyses Overview Single-molecule TIRF microscopy, labeling procedures, and co-localization/ co-tracking analyses were conducted as recently described (Moraga et al., 2015b) . Single-molecule localization and single-molecule tracking were carried out using the multipletarget tracing (MTT) algorithm (Sergé et al., 2008) , as described previously (You et al., 2014) . Immobile molecules were identified by the density-based spatial clustering of applications with noise (DBSCAN) (Sander et al., 1998) algorithm, as described recently (Roder et al., 2014) . For co-tracking analysis, immobile particles were excluded from the dataset. Individual molecules detected in the both spectral channels were regarded as co-localized if a particle was detected in both channels of a single frame within a distance threshold of a 100 nm radius. The population of co-localized particles was linked frame-by-frame to co-trajectories (threshold: R 10 consecutive steps).
Plasmid Constructs
For single molecule fluorescence microscopy, monomeric non-fluorescent (Y67F) variant of eGFP (''mXFP'') was N-terminally fused to EPOR. This construct was inserted into a modified version of pSems-26 m (Covalys) including a signal peptide of Igk. The ORF was linked to a neomycin resistance cassette via an IRES site. The construct JAK2-meGFP was co-expressed to ensure full functionality of the receptor system. For negative controls, we used a fusion construct of meGFP linked to an artificial transmembrane domain K(ALA) 7 KSSR. Cultivation of Cells for Single-Molecule Imaging HeLa cells were cultivated at 37 C and 5% CO 2 in Minimal Essential Medium with Earle's Salts (EMEM) with stable glutamine supplemented with 10% fetal bovine serum (FBS), non-essential amino acids and HEPES buffer without addition of antibiotics. HeLa cells were stably transfected with mXFP-EPOR by selection with G418 (800mg/ml). For minimizing the background fluorescence from non-specifically adsorbed dye molecules in single molecule imaging experiments, glass coverslides were coated with a poly-L-lysine-graft-(polyethylene glycol) copolymer functionalized with RGD as described previously (You et al., 2014) . Cells were seeded in 60 mm cell-culture dishes to a density of approximately 60% confluence and transiently transfected with JAK2-meGFP via calcium-phosphate-precipitation according to standard protocols. Transfected cells were transferred to coated 35 mm glass coverslides. Single molecule imaging experiments were conducted 48 hr post transfection. Imaging was performed in custom-designed microscopy chambers with a volume of 1 ml. Protein Purification & Labeling An anti-GFP nanobody (antiGFP-NB) (Rothbauer et al., 2008) fused to a C-terminal ybbR-tag (Yin et al., 2005) for site-specific labeling by enzymatic phosphopantetheinyl-transfer was cloned into the pBAC vector. Generation of a baculovirus and protein expression in Sf9 cells were carried out as described above. The protein was purified to homogeneity by immobilized metal ion affinity chromatography and labeled using coenzyme A conjugated to DY 647 and ATTO Rho11, respectively, according to published protocols (Yin et al., 2005) . A typical labeling degree of > 90% was achieved.
Single Molecule Imaging Experiments
Single molecule imaging experiments were carried out by total internal reflection fluorescence (TIRF) microscopy with an inverted microscope (Olympus IX71) equipped with a triple-line total internal reflection (TIR) illumination condenser (Olympus) and a back-illuminated electron multiplied (EM) CCD camera (iXon DU897D, 512 3 512 pixel, Andor Technology). A 150 3 magnification objective with a numerical aperture of 1.45 (UAPO 150 3 /1.45 TIRFM, Olympus) was used for TIR illumination of the sample. All experiments were carried out at room temperature in medium without phenol red supplemented with an oxygen scavenger and a redox-active photoprotectant to minimize photobleaching (Vogelsang et al., 2008) . For cell surface labeling of mXFP-EPOR, DY647 antiGFP-NB and RHO11 antiGFP-NB were added to the medium at equal concentrations (2 nM) and incubated for at least 5 min. The nanobodies were kept in the bulk solution during the whole experiment in order to ensure high equilibrium binding to mXFP-EPOR (Moraga et al., 2015b) . Dimerization of EpoR was probed before and after incubation with indicated EPO mutants and concentrations. Model transmembrane protein, comprised of a N-terminal meGFP-tag, linked to an artificial transmembrane domain (ALA) 7 KSSR was labeled as described above and taken as negative control for co-tracking experiments. Image stacks of 150 frames were recorded at 32 ms/frame. For simultaneous dual-color acquisition, RHO11 antiGFP-NB was excited by a 561 nm diode-pumped solid-state laser at 0.95 mW ($32W/cm 2 ) and antiGFP-NB by a 642 nm laser diode at 0.65 mW ($22W/cm 2 ). Fluorescence was detected using an spectral image splitter (DualView, Optical Insight) with a 640 DCXR dichroic beam splitter (Chroma) in combination with the bandpass filter 585/40 (Semrock) for detection of RHO11 and 690/70 (Chroma) for detection of DY647 dividing each emission channel into 512x256 pixel.
QUANTIFICATION AND STATISTICAL ANALYSIS
Single Molecule Tracking, Co-Localization and Co-Tracking Analyses Single molecule localization and single molecule tracking were carried out using the multiple-target tracing (MTT) algorithm (Sergé et al., 2008) , as described previously (Wilmes et al., 2015) . Immobile molecules were identified by the density-based spatial clustering of applications with noise (DBSCAN) (Sander et al., 1998) algorithm as described recently (Roder et al., 2014) . For co-tracking analysis, immobile particles were excluded from the dataset.
Prior to co-localization analysis, imaging channels were aligned with sub-pixel precision by using a spatial transformation. To this end, a transformation matrix was calculated based on a calibration measurement with multicolor fluorescent beads (TetraSpeck microspheres 0.1 mm, Invitrogen) visible in both spectral channels (cp2tform of type 'affine', The MathWorks MATLAB 2009a).
Individual molecules detected in the both spectral channels were regarded as co-localized, if a particle was detected in both channels of a single frame within a distance threshold of a 100 nm radius. For single molecule co-tracking analysis, the MTT algorithm was applied to this dataset of co-localized molecules to reconstruct co-locomotion trajectories (co-trajectories) from the identified population of co-localizations. For the co-tracking analysis, only trajectories with a minimum of 10 steps ($300 ms) were considered. The relative fraction of co-tracked molecules was determined with respect to the absolute number of trajectories and corrected for EPOR stochastically double-labeled with the same fluorophore species as follows:
where A, B, and AB are the numbers of trajectories observed for RHO11, DY647 and co-trajectories, respectively.
Statistical Analysis of Binding and Kinetic Data
The data points were fitted using the binding-saturation curve sigmoidal fits with the one site-total method (GraphPad Prism 7). The significance was calculated with a two sided Student's t test.
Whole-Exome Sequencing Analysis
The patient described here is part of a DBA cohort that underwent whole exome sequencing (raw sequence data has been deposited under dbGAP accession phs000474.v2.p1) (Doherty et al., 2010; Sankaran et al., 2012) . Coverage across the consensus coding DNA sequences (CDS; downloaded from UCSC genome browser on December 13, 2015) plus an additional 20 nucleotides on each side of the exons was calculated using Picard tools (Table S1 ). The variant call file (VCF) was annotated with Variant Effect Predictor v83 and the dbNSFP database v3.1 (Liu et al., 2011; McLaren et al., 2010) . A combination of the genome analysis toolkit (GATK) and Plink were then used to identify rare (based upon the ExAC v0.3 release of 60,706 individuals) variants (DePristo et al., 2011; Purcell et al., 2007) . No rare (defined as 0.01% allele frequency in ExAC) damaging (missense or loss of function) mutations were present in the patient in any of the known DBA genes (RPS19, RPL5, RPL11, RPL35A, RPS26, RPS24, RPS17, RPS7, RPS10, RPL26, RPS29, RPS28, RPS27, RPL27, RPL15, RPL31, GATA1, TSR2) , or in any other ribosome protein coding genes. Since the proband is the child of consanguineous parents, we next searched for putative recessive mutations in the known red cell disorder genes (ANK1, SPTB, SPTA1, SLC4A1, EPB42, EPB41, PIEZO1, KCNN4, GLUT1, G6PD, PKLR, NT5C3A, HK1, GPI, PGK1, ALDOA, TPI1, PFKM, ALAS2, FECH, UROS, CDAN1, SEC23B, KIF23, KLF1, GATA1, HBB, HBA1, HBA2) , but again did not identify any rare damaging mutations. Having ruled out previously identified causal genes, we expanded our search space to all putative rare and damaging recessive mutations (Table S2 ) and identified chr7:100320704:G>A in the EPO gene as the leading candidate mutation (Table S3) . Follow-up Sanger sequencing confirmed the mutation and showed that this mutation showed appropriate segregation in the family, consistent with a model of complete penetrance. 10 -10 10 -9 10 -8 10 -6 10 -7
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A Particles were considered to be co-localized if found in both spectral channels in the same frame within a distance threshold of 100 nm. The population of colocalized particles was then linked frame-by-frame to co-trajectories (threshold R 10 consecutive steps, $320 ms).
